Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

Opinion
Video

Elizabeth Plimack, MD, reviews a network meta-analysis comparing progression free survival and overall survival outcomes for lenvatinib plus pembrolizumab versus other first line regimens for metastatic clear cell renal cell carcinoma across multiple trials.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content
Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.

Gemcitabine Intravesical System Combo Shows High pCR Rate in MIBC

Kristi Rosa
October 17th 2025
Article

Updated results from SunRISe-4 support further investigation of the gemcitabine intravesical system plus cetrelimab in MIBC.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC

Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC

Ben Saylor
October 17th 2025
Article

New findings reveal that adding durvalumab to neoadjuvant chemotherapy does not enhance HRQOL in muscle-invasive bladder cancer patients.

Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.

Nivolumab Sustains DFS Benefits in Muscle-Invasive Urothelial Carcinoma

Russ Conroy
October 17th 2025
Article

Updated results from CheckMate 274 support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial carcinoma.